上海市锦天城（成都）律师事务所 关于永和流体智控股份有限公司 2024年第二次临时股东大会之 法律意见书 上海市锦天城（成都）律师事务所 地址：成都市高新区交子大道 33 号华商金融中心一号楼 31 层 电话：028-85939898 传真：028-62022900 邮编：610041 上海市锦天城（成都）律师事务所 关于永和流体智控股份有限公司 2024 年第二次临时股东大会之 法律意见书 致：永和流体智控股份有限公司 鉴此，本所律师根据上述法律、法规及其他规范性文件的要求，按照律师行 业公认的业务标准、道德规范和勤勉尽责精神，出具法律意见如下： 上海市锦天城（成都）律师事务所（以下简称"本所"）接受永和流体智控 股份有限公司（以下简称"公司"）的委托，就公司召开 2024 年第二次临时股 东大会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《上市公司股东大会规则》等法律、法规和 其他规范性文件以及《永和流体智控股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 ...

证券代码：002795 证券简称：永和智控 公告编号：2024-038 永和流体智控股份有限公司 2024年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的时间： 现场会议召开时间：2024 年 10 月 9 日（星期三）14:50 网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间：2024年10月9 日上午9:15-9:25，9:30-11:30和下午13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2024年10月9 日上午9:15至下午15:00期间的任意时间。 2、现场会议召开地点：四川省成都市高新区天府三街88号5栋23层公司会议 室。 3、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 4、会议召集人：永和流体智控股份有限公司董事会 5、会议主持人：魏璞女士 误导性陈述或重大遗漏。 （二）会 ...

公司第五届董事会第十二次临时会议审议通过了《关于召开公司2024年第二 次临时股东大会的议案》，同意召开本次股东大会。 3、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的相关规定。 4、会议召开的时间： 证券代码：002795 证券简称：永和智控 公告编号：2024-037 永和流体智控股份有限公司 关于召开2024年第二次临时股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024年第二次临时股东大会 2、股东大会的召集人：公司董事会 （1）现场会议时间：2024年10月9日（星期三）14:50 （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间：2024年10月9日上 午9:15-9:25，9:30-11:30和下午13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2024年10月9日上 午9:15至下午15:00期间的任意时间。 5、会议的召开方式：本次股东大会采用现场表决与网络投票相结合 ...

证券代码：002795 证券简称：永和智控 公告编号：2024-035 永和流体智控股份有限公司 第五届董事会第十二次临时会议决议公告 二、董事会会议审议情况 在保证全体董事充分发表意见的前提下，本次会议形成如下决议： （一）以 7 票同意、0 票反对、0 票弃权的表决结果，审议通过了《关于公 司、全资子公司、控股孙公司为达州医科融资授信额度提供担保的议案》。 为满足公司控股孙公司达州医科肿瘤医院有限公司（以下简称"达州医科"） 日常经营和业务发展的资金需求，同意公司、公司全资子公司成都永和成医疗科 技有限公司（以下简称"成都永和成"）、控股孙公司凉山高新肿瘤医院有限公司 （以下简称"凉山高新"）为达州医科向银行申请的融资授信额度提供人民币 800 万元的全额连带责任保证担保。 具体内容详见公司同日刊登于巨潮资讯网（http://www.cninfo.com.cn）、《证 券时报》和《证券日报》的《关于公司、全资子公司为控股孙公司融资授信额 度提供担保及控股孙公司互保的公告》（公告编号：临 2024-036 号）。 （二）以 7 票同意、0 票反对、0 票弃权的表决结果，审议通过了《关于公 1 本公司及董事会 ...

证券代码：002795 证券简称：永和智控 公告编号：2024-036 关于公司、全资子公司为控股孙公司融资授信额度提供担保 及控股孙公司互保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 全额连带责任保证担保，担保期限均为 12 个月。具体担保内容以届时各方签订 的担保合同为准。 根据《深圳证券交易所股票上市规则》、《公司章程》相关规定，本次担保 事项已经公司第五届董事会第十二次临时会议审议通过，《关于公司、全资子公 司、控股孙公司为达州医科融资授信额度提供担保的议案》无需提交公司股东大 会审议，《关于公司、全资子公司、控股孙公司为凉山高新融资授信额度提供担 保的议案》尚需提交公司 2024 年第二次临时股东大会审议。 永和流体智控股份有限公司 特别提示：永和流体智控股份有限公司本次对控股孙公司凉山高新肿瘤医院 有限公司提供担保，属于对资产负债率超过 70%的对象提供担保。敬请投资者充 分关注担保风险。 永和流体智控股份有限公司（以下简称"公司"）于 2024 年 9 月 23 日召开第 五届董事会第十二次临时会议，审议通过了《关于公司、全资子公 ...

证券代码：002795 证券简称：永和智控 公告编号：2024-034 永和流体智控股份有限公司 关于收到不可撤销地放弃表决权承诺函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、概述 2024 年 5 月 26 日，永和流体智控股份有限公司（以下简称"永和智控"或 "公司"）持股 5%以上股东应雪青与颜燕晶签署了《股份转让协议》，应雪青拟 将其持有的永和智控 24,500,000 股无限售流通股股份（占公司股份总数的 5.50%）以每股 4.45 元的价格协议转让给颜燕晶。本次股份转让后，颜燕晶为 公司持股 5%以上股东。 具体内容详见公司 2024 年 5 月 29 日 披 露 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的《关于持股 5%以上股东签署<股份转让协议> 暨权益变动的提示性公告》（公告编号：2024-025）。 公司于 2024 年9月5日收到颜燕晶女士（以下简称"承诺人"）出具的 《承诺函》。颜燕晶承诺自受让应雪青持有的24,500,000股股份（占公司股 份总数的5.50%）后，不可撤销地放弃 ...

Financial Performance - Revenue for the reporting period decreased by 15.42% to RMB 421,098,177.10 compared to the same period last year[11] - Net profit attributable to shareholders of the listed company decreased by 149.99% to RMB -56,234,054.72[11] - Net cash flow from operating activities decreased by 74.01% to RMB -53,554,532.87[11] - Basic earnings per share decreased by 160.00% to RMB -0.13[11] - Total assets decreased by 5.84% to RMB 1,769,938,443.19 compared to the end of the previous year[11] - Net assets attributable to shareholders of the listed company decreased by 6.28% to RMB 743,421,718.54[11] - Weighted average return on equity decreased by 4.67 percentage points to -7.32%[11] - The company reported a total operating revenue of 421.0982 million yuan for the reporting period, a 15.42% year-on-year decrease, and a net loss attributable to the parent company of 56.2341 million yuan, a 149.99% year-on-year decrease[27] - The company's revenue for the reporting period was 421,098,177.10 yuan, a decrease of 15.42% compared to the same period last year[36] - Net profit attributable to parent company shareholders was -56,234,054.72 yuan, a decrease of 150.1% compared to the same period last year[113] - Comprehensive income totaled -59,631,507.14 yuan, down 71.8% year-over-year[113] - Basic earnings per share were -0.13 yuan, a decline of 160% from the previous year[113] - Operating cash flow was -53,554,532.87 yuan, a 74.1% decrease compared to the same period last year[117] - Sales revenue from goods and services was 410,914,483.57 yuan, down 4.5% year-over-year[117] - Management expenses were 9,304,617.83 yuan, a 54.4% decrease from the previous year[115] - Financial expenses were -67,925.18 yuan, a 106.7% decrease compared to the same period last year[115] - Credit impairment losses were -41,537,992.23 yuan, a significant increase from 400,000.00 yuan in the previous year[115] - Operating profit was -50,767,917.07 yuan, a 146.7% decrease year-over-year[115] - Diluted earnings per share were -0.12 yuan, a 140% decrease from the previous year[116] - Net cash flow from investment activities was -51.65 million yuan, a decrease of 145.32 million yuan compared to the same period last year[118] - Net cash flow from financing activities was 82.88 million yuan, a decrease of 143.19 million yuan compared to the same period last year[118] - The ending balance of cash and cash equivalents was 214.13 million yuan, a decrease of 276.57 million yuan compared to the same period last year[118] - Net cash flow from operating activities was -6.03 million yuan, an improvement from -13.88 million yuan in the same period last year[119] - Net cash flow from investment activities was 12.46 million yuan, compared to -28.91 million yuan in the same period last year[120] - Net cash flow from financing activities was -6.36 million yuan, compared to -36.96 million yuan in the same period last year[120] - The ending balance of cash and cash equivalents was 1.57 million yuan, a decrease of 2.37 million yuan compared to the same period last year[120] - The total owner's equity at the beginning of the period was 804.20 million yuan[121] - Comprehensive income for the period decreased by RMB 56,234,054.72[122] - Owner's equity increased by RMB 6,505,493.48 due to capital contributions[122] - Total owner's equity at the end of the period was RMB 751,073,608.11[123] - Capital reserve decreased by RMB 26,134,335.62[124] - Net profit attributable to parent company owners decreased by RMB 22,494,471.61[124] - Owner's equity at the end of the period was RMB 893,813,878.94[126] - Other comprehensive income decreased by RMB 199,978.49[124] - Total owner's equity at the beginning of the period was RMB 823,002,383.80[124] - Capital reserve at the end of the period was RMB 358,477,395.76[126] - Retained earnings at the end of the period were RMB 94,490,134.36[126] - Share capital increased to 445,754,078.00 yuan, with a capital reserve of 365,681,673.47 yuan[127] - Comprehensive income for the period decreased by 50,767,874.07 yuan, impacting total owner's equity[127] - Owner's equity at the end of the period was 722,036,757.17 yuan, down from 766,299,137.76 yuan at the beginning[128] - Total owner's equity increased to 836,453,636.35 yuan by the end of the period, up from 742,548,731.20 yuan at the beginning[130] - Capital reserve decreased by 21,785,686.88 yuan during the period[129] - Owner's equity was impacted by a decrease in undistributed profits by 20,579,779.97 yuan[129] - Owner's equity was bolstered by owner contributions of 114,484,685.12 yuan[129] Market and Industry Trends - The global water fittings market reached 98.442 billion RMB in 2022 and is expected to grow at a CAGR of 5% to reach 131.433 billion RMB by 2028[16] - The US water fittings market was valued at 20.1 billion USD in 2020, accounting for 27.02% of the global market share[17] - The European water fittings market was approximately 19 billion USD in 2020, representing about a quarter of the global market[17] - The Chinese water fittings market was 13 billion USD in 2020 and is projected to grow at a CAGR of 7.8% to reach 21.9 billion USD by 2027[17] - The number of elderly people aged 60 and above in China reached 297 million, accounting for 21.1% of the total population in 2023[20] - In 2022, there were 4.8247 million new cancer cases in China, with the overall cancer incidence rate on the rise[20] - Approximately 70% of cancer patients require radiotherapy at different stages of the disease, and radiotherapy can cover 95% of cancer treatments[20] - The precision radiotherapy market in China accounted for 74.0% of the total radiotherapy market in 2022, and is expected to grow to 79.7% by 2030[20] - The market size of precision tumor radiotherapy in China reached 41 billion yuan in 2022, with a CAGR of 13.28% from 2018 to 2022, and is projected to grow to 80.9 billion yuan by 2025[20] - China's cumulative installed power generation capacity reached approximately 2.92 billion kW by the end of 2023, with solar power capacity at about 610 million kW, a 55.2% year-on-year increase, and wind power capacity at 440 million kW, a 20.7% year-on-year increase[23] Business Operations and Strategy - The company's valve and pipe fitting business primarily serves the civil construction water and gas systems, with products mainly exported to European and American markets[17] - The company adopts a make-to-order production principle, with a production model that is primarily self-manufactured and supplemented by outsourcing[17] - The company is located in Yuhuan City, Zhejiang Province, one of the largest water valve production and sales bases in China[19] - The company operates specialized cancer hospitals in multiple locations, including Dazhou, Kunming, Xi'an, and Liangshan, focusing on precision radiotherapy[21] - The company's hospitals are equipped with advanced medical imaging and radiotherapy devices, such as PET-CT, 3.0T MRI, and linear accelerators[21] - The company adopts a business model of "external acquisitions + internal growth" to expand its chain of specialized cancer hospitals[21] - The company has established medical consortium agreements with top-tier hospitals to enhance collaboration in technology, talent, and patient referrals[21] - The company plans to introduce more advanced precision radiotherapy equipment to strengthen its comprehensive cancer treatment capabilities[21] - The company has acquired four specialized cancer hospitals, including Dazhou Medical Cancer Hospital, Kunming Medical Cancer Hospital, Liangshan High-tech Cancer Hospital, and Xi'an Medical Cancer Hospital, establishing a preliminary chain and scale in the field of precision radiotherapy for tumors[22] - The company's N-type TOPCon solar cells have achieved a maximum conversion efficiency of 25.66%, with applications in residential, commercial, and centralized photovoltaic modules[24] - The company's valve and pipe fittings business faces reduced profitability due to tightening U.S. tariff policies, prompting a focus on expanding the domestic market and building overseas factories and brands[27] - Kunming Medical Cancer Hospital has enhanced its market influence by integrating online and offline expert resources, shifting from passive to active patient acquisition[27] - Liangshan High-tech Cancer Hospital plans to establish a provincial expert consultation model to improve its brand influence in Xichang[27] - The company's photovoltaic business is burdened with high fixed costs, leading to efforts in risk control and product competitiveness enhancement[27] - The company's valve and pipe fittings business has a stable customer base with large multinational corporations, though the U.S. market advantage is declining due to trade friction[28] - The company's precision radiotherapy services are positioned to capitalize on the growing demand for non-public cancer hospitals amid China's aging population and rising cancer incidence[29] - The company's photovoltaic battery segment revenue increased by 93.24% to 5,342,888.58 yuan[37] - The company sold 51% equity of Pule New Energy Technology (Taixing) Co., Ltd. to Shanghai Guosheng Xusheng Energy Technology Co., Ltd. for 0 RMB, aiming to optimize industrial structure and improve resource allocation[47] - Zhejiang Anhong Plumbing Equipment Co., Ltd., a subsidiary, reported a net profit of 6,945,067.78 RMB with total assets of 169,040,798.95 RMB and revenue of 113,281,018.11 RMB[49] - Zhejiang Yonghe Intelligent Control Technology Co., Ltd., another subsidiary, achieved a net profit of 11,915,712.43 RMB with total assets of 826,931,475.48 RMB and revenue of 224,528,892.92 RMB[49] - Pule New Energy Technology (Taixing) Co., Ltd. reported a net loss of 41,537,992.23 RMB with total assets of 409,482,088.71 RMB and revenue of 5,342,888.58 RMB[49] - The company faces risks from changes in the foreign trade environment, with the U.S. market accounting for approximately 50% of its sales[51] - The company mitigates exchange rate fluctuation risks by implementing a currency linkage mechanism with customers and using hedging tools[52] - Copper rod costs account for about 60% of production costs, and the company manages raw material price risks through dynamic tracking and strategic inventory partnerships[53] - The company faces potential risks of delayed medical insurance reimbursements as its hospital business expands[54] - The company has a significant amount of goodwill from acquiring specialized cancer hospitals and aims to reduce the risk of goodwill impairment by improving hospital profitability[55] - The company plans to apply for a comprehensive credit line not exceeding 600 million yuan for the full year of 2024[57] - The company will continue to engage in forward foreign exchange settlement and sales business[57] - The company has approved a proposal to authorize the board to issue shares to specific objects through a simplified procedure[58] - The company will not distribute cash dividends, issue bonus shares, or convert capital reserve into share capital in the first half of the year[60] - The company's 2022 restricted stock incentive plan was adjusted to grant 16.016 million shares at a price of 3.98 yuan per share to 56 incentive objects[61] - The company decided to repurchase and cancel 16,800 shares of restricted stock from 2 departed incentive objects[62] - The number of restricted shares granted under the 2022 restricted stock incentive plan was adjusted from 16.016 million shares to 22.4224 million shares[63] - The grant price of the 2022 restricted stock incentive plan was adjusted from RMB 3.98 per share to RMB 2.84 per share[63] - 52,920 restricted shares were repurchased and canceled due to the departure of 3 incentive recipients[63] - 1,118.474 million restricted shares were unlocked and became tradable in the first unlocking period of the 2022 restricted stock incentive plan[63] - 184.2247 million restricted shares were repurchased and canceled due to the departure of 4 incentive recipients and unmet performance targets[63] - 711.8089 million restricted shares were unlocked and became tradable in the second unlocking period of the 2022 restricted stock incentive plan[63] - The company actively participated in nearly 40 public welfare activities in the first half of 2024, including patient care, free clinics, and health education[67] - The company strictly complied with labor laws and established a comprehensive human resource management system to protect employee rights[67] - The company has established a comprehensive quality management system for its valve and pipe fittings products, ensuring high-quality medical technology, services, and products[68] - The company has formed strategic partnerships with large domestic and international medical equipment suppliers to provide advanced tumor precision radiotherapy facilities and technologies[68] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[69] - The company's semi-annual financial report was not audited[69] - The company won a lawsuit involving a private equity fund, with no liability for damages, involving an amount of 1.4819 million yuan[70] - The company is involved in multiple ongoing lawsuits with material suppliers, with amounts ranging from 7.15 thousand yuan to 1.09596 million yuan[70] - The company confirmed 526.1 thousand yuan in employee compensation payable as of June 30, 2024, related to labor arbitration at Xi'an Medical Cancer Hospital[71] - The company confirmed 1.6324 million yuan in other current liabilities as of June 30, 2024, related to a rent dispute arbitration at Xi'an Medical Cancer Hospital[71] - The company reported no penalties or rectifications during the reporting period[72] - The company had no significant related-party transactions during the reporting period[73][74][75] - The company continues to lease office space in Shanghai with a 5-year lease agreement[80] - The company leases operating premises for Dazhou Medical Cancer Hospital with a 10-year lease agreement[80] - The company leases operating premises for Kunming Medical Cancer Hospital with a 13-year lease agreement[80] - The company leases part of Chengdu Shanshui Shang property to Chengdu Gaoshang Medical Imaging Diagnosis Center and Chengdu Gaoxin Heyue Gaoshang Physical Examination Clinic with a 13.5-year lease agreement[80] - The company leases operating premises for Liangshan Gaoxin Cancer Hospital with a 10-year lease agreement[80] - The company leases operating premises for Xi'an Medical Cancer Hospital with a 15-year lease agreement currently under arbitration[80] - The company leases production plant for Pule Taixing with a 10-year lease agreement[80] - The company leases office space in Chengdu with a 3-year lease agreement[80] - The total approved guarantee amount for subsidiaries at the end of the reporting period is 1,600 million yuan[81] - The actual guarantee balance for subsidiaries at the end of the reporting period is 1,600 million yuan[81] - Shareholder Xia Zuwang holds 23,635,966 shares, accounting for 5.30% of the company's total shares, becoming the fourth largest shareholder[87] - The company will not distribute profits for 2023, including no cash dividends, no stock dividends, and no capital reserve to share capital conversion[87] - The company and its subsidiaries have applied for a comprehensive credit line of up to RMB 600 million for 2024[87] - The company will conduct forward foreign exchange contracts with a cumulative amount not exceeding USD 100 million to mitigate exchange rate risks[88] - The company is authorized to issue shares to specific objects with a financing amount not exceeding RMB 300 million and 20% of the net assets at the end of the previous year[88] - Shareholder Ying Xueqing transferred 24,500,000 shares (5.50% of total shares) to Yan Yanjing at a price of RMB 4.45 per share[88] - The company plans to transfer 51% equity of Pule Technology to Guosheng Xusheng Energy Technology, removing Pule Technology from the consolidated financial statements[89] - The company's total shares remain unchanged at 445,754,078, with 96.70% being unrestricted shares[90] - The company's limited-sale shares remain at 14,712,740, accounting for 3.30% of total shares[90] - Key executives hold restricted shares due to senior management lock-up and equity incentive restrictions[91] - Total restricted shares for equity incentive plan amount to 14,712,740 shares[93] - The total number of ordinary shareholders at the end of the reporting period is 25,228[94] - Cao Deli holds 9.65% of the company's shares, totaling 43,004,034 shares[94] - Chen Xianyun holds 7.34% of the company's shares, totaling 32,717,104 shares[97] - Ying Xueqing holds 5.50% of the company's shares, totaling 24,500,000 shares[97] - Xia Zuwang holds 5.30% of the company's shares, totaling 23,635,966 shares[97] - Su Jinfei holds 4.52% of the company's shares, totaling 20,127,240 shares[97] - Yang Yingli holds 3.70% of the company's shares, totaling 16,492,500 shares[97] - Yu Yaqun holds 3.30% of the company's shares, totaling 14,700,000 shares[97] - Deng Lili holds 0

本表已于 2024年8月28 日获董事会批准。 法定代表人: 主管会计工作负责人 永和流体智控股份有限公司 2024年1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位:万元 | 非经营性资金占用 | 资金占用方名称 | | | | 占用方与上市公 上市公司核算的 2024 年 1 月 1 日 2024 年 1-6 月往来资\2024 年 1-6 月往来资\2024 年 1-6 月 20 住 | | | | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 往来资金余额 | 生金额(不含利息) | 金的利息(如有) | 计发生金额 | 来资金余额 | | | | 控股股东、实际控制人 | | | A THE REAL PRODUCTION | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制 | | | | | | | | ...

证券代码：002795 证券简称：永和智控 公告编号：2024-031 永和流体智控股份有限公司 关于控股股东、实际控制人的一致行动人权益变动超过1% 的公告 公司控股股东、实际控制人的一致行动人余娅群保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 永和流体智控股份有限公司（以下简称"公司"）于近日收到本公司控股股东、 实际控制人曹德莅的一致行动人余娅群出具的《告知函》，获悉：2024年8月16 日至2024年8月23日，余娅群在诚通证券股份有限公司（以下简称"诚通证券"） 客户信用交易担保证券账户所持有的部分公司股份被诚通证券强制平仓，被动减 持公司股份数量为5,640,000股，占公司总股本的比例为1.27%，被动减持获得资 金全部用于偿还余娅群在诚通证券的融资负债。 根据《证券法》《深圳证券交易所上市公司自律监管指引第1号——主板上 市公司规范运作》《上市公司收购管理办法》《上市公司股东减持股份管理暂行 办法》《深圳证券交易所上市公司自律监管指引第18号——股东及董事、监事、 高级管理人员减持股份》 ...